PBAC's latest decision on Nicotine, transdermal patch: Recommended with restriction (2010). Considered for as an aid to cessation of smoking in patients who have entered or are entering a comprehensive support and counselling program in the context of a public health priority area.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2010
Submissions
1
2010 → 2010
Eligible population
smokers motivated to quit smoking
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
RCT, Meta-analysis
Primary endpoint
Continuous abstinence rate (CAR)
Key trials
Aubin et al. 2008
Comparator
varenicline
Economic model
Cost-minimisation
Budget impact
$-10000000
ICER note
Cost-analysis provided (not full economic evaluation with ICER). Document states 'nicotine patches are less effective, of superior safety and less expensive than varenicline' but no numeric ICER calculated.